首页> 外文期刊>Experimental and therapeutic medicine >Doxazosin attenuates renal matrix remodeling mediated by anti-alpha(1)-adrenergic receptor antibody in a rat model of diabetes mellitus
【24h】

Doxazosin attenuates renal matrix remodeling mediated by anti-alpha(1)-adrenergic receptor antibody in a rat model of diabetes mellitus

机译:Doxazosin衰减由糖尿病大鼠模型中的抗α(1) - 肾上腺素能受体抗体介导的肾脏基质重塑

获取原文
获取原文并翻译 | 示例
           

摘要

Diabetic nephropathy is a major complication of diabetes mellitus (DM). Repent studies suggest that immunological mechanisms have a key role in the pathogenesis of DM, therefore these mechanisms may be important targets for diabetes therapy. The present study evaldated the effects of anti-aradrenergic receptor antibody (alpha(1)-R Ab) mediation and doxazosin treatment in a rat model of DM. It was observed that levels of 24-h urinary protein, serum creatinine and transforming growth factor-beta(1), in DM were significantly increased after alpha(1)-R Ab mediation (all P<0.05). In addition, electron microscopy identified severe damage in the renal tissue microstructures of DM rats following alpha(1)-R Ab mediation, while only mild abnormalities were observed in that of healthy rats mediated with alpha(1)-R Ab and of untreated DM rats. No marked abnormalities were observed in the renal tissue of healthy blank controls. Furthermore, in DM rats treated with alpha(1)-R Ab mediation + doxazosin intervention, the expression of TGF-beta(1) significantly decreased, and renal functions and renal matrix remodeling were significantly improved, relative to untreated DM controls (P<0.01). These results suggest that alpha(1)-R Ab may be involved in renal matrix remodeling during DM, and that kidney protection during DM may be achieved through treatment with corresponding receptor antagonists.
机译:糖尿病肾病是糖尿病(DM)的主要并发症。悔改的研究表明,免疫机制在DM的发病机制中具有关键作用,因此这些机制可能是糖尿病疗法的重要靶标。本研究评估了抗Aradradraderic受体抗体(α(1)-R AB)中介和二象素治疗在DM的大鼠模型中的影响。观察到α(1)-R AB调解后,DM中的24-H尿蛋白,血清肌酐和转化生长因子-β(1)的水平显着增加(所有P <0.05)。此外,电子显微镜鉴定在α(1)-Rb中的Dm大鼠肾组织微观结构中鉴定严重损伤,同时在用α(1)-R ab和未处理的DM中介导的健康大鼠中观察到轻度异常老鼠。在健康空白对照的肾组织中没有观察到明显的异常。此外,在用α(1)-RB中介+ doxazosin干预处理的DM大鼠中,相对于未处理的DM对照,TGF-β(1)的表达显着降低,肾功能和肾脏基质重塑显着改善(P < 0.01)。这些结果表明,α(1)-R AB可以参与DM期间的肾脏基质重塑,并且可以通过用相应的受体拮抗剂治疗来实现DM期间的肾脏保护。

著录项

  • 来源
  • 作者单位

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

    Guangzhou Mil Command Wuhan Gen Hosp Med Expt Ctr Wuhan 430070 Hubei Peoples R China;

    Guangzhou Mil Command Wuhan Gen Hosp Dept Endocrinol 627 Wuluo Rd Wuhan 430070 Hubei Peoples;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

    alpha(1) adrenergic receptor; autoantibody; diabetes mellitus; renal matrix remodeling; doxazosin;

    机译:α(1)肾上腺素能受体;自身抗体;糖尿病;肾脏基质重塑;doxazosin;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号